Pacific Biosciences (PACB - Get Report) is feeling so confident about its offering, that its lifted its original filing from $200 million to $230 million. Biotech IPOs haven't received warm welcomes of late and Pacific Biosciences is in an increasingly crowded DNA sequencing field.
This Week's IPO Winners and Losers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.